View Older Stories View More Recent Stories

May 17, 2021 09:04AM Esperion Therapeutics (ESPR) Appoints Sheldon Koenig as President and CEO
May 17, 2021 09:01AM ESPERION Appoints Sheldon Koenig as President and CEO
May 17, 2021 09:01AM ESPERION Appoints Sheldon Koenig as President and CEO
May 15, 2021 12:00PM Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
May 15, 2021 12:00PM Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21
May 6, 2021 08:00AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
May 6, 2021 08:00AM Esperion to Participate in Two Upcoming Virtual Investor Conferences
May 4, 2021 04:01PM ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
May 4, 2021 04:01PM ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
Apr 28, 2021 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 28, 2021 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 27, 2021 08:00AM Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
Apr 27, 2021 08:00AM Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
Apr 26, 2021 04:27PM Esperion Therapeutics (ESPR) Secures $50 Million Funding from Oberland Capital
Apr 26, 2021 04:07PM Esperion Secures $50 Million Funding from Oberland Capital
Apr 26, 2021 04:07PM Esperion Secures $50 Million Funding from Oberland Capital
Apr 26, 2021 04:02PM Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Apr 26, 2021 04:02PM Esperion Expands Partnership with Daiichi Sankyo Group to Additional Territories
Apr 12, 2021 04:01PM Esperion to Report First Quarter 2021 Financial Results May 4, 2021
Apr 12, 2021 04:01PM Esperion to Report First Quarter 2021 Financial Results May 4, 2021
Apr 6, 2021 08:00AM Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
Apr 6, 2021 08:00AM Esperion to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
Mar 17, 2021 04:11PM Esperion Therapeutics (ESPR) Announces NEXLETOL Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
Mar 17, 2021 04:05PM NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
Mar 17, 2021 04:05PM NEXLETOL® (bempedoic acid) Tablet, ezetimibe and atorvastatin combination lowered bad cholesterol by 60.5% vs. placebo in Phase 2 study
Feb 23, 2021 04:01PM ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Feb 23, 2021 04:01PM ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
Feb 9, 2021 08:00AM Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
Feb 9, 2021 08:00AM Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021
Jan 29, 2021 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 29, 2021 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 13, 2021 06:28AM Esperion Therapeutics (ESPR) Preliminary Q4 Financial Results
Jan 13, 2021 06:26AM ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
Jan 13, 2021 06:26AM ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program
Dec 21, 2020 08:00AM Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 21, 2020 08:00AM Esperion to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 16, 2020 06:42AM Esperion Therapeutics (ESPR) announces first-in-class cholesterol-lowering treatment NILEMDO tablet and its combination with ezetimibe NUSTENDI tablet approved in Switzerland
Dec 16, 2020 03:00AM First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
Dec 16, 2020 03:00AM First-in-class cholesterol-lowering treatment NILEMDO® * (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® * (bempedoic acid and ezetimibe) tablet approved in Switzerland
Dec 15, 2020 07:02AM Esperion Therapeutics (ESPR) Announces Sheldon Koenig as COO
Dec 15, 2020 07:00AM ESPERION Appoints Sheldon Koenig as Chief Operating Officer
Dec 15, 2020 07:00AM ESPERION Appoints Sheldon Koenig as Chief Operating Officer
Nov 13, 2020 09:16AM Esperion Therapeutics (ESPR) NEXLETOL Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant LDL-C Lowering vs. Placebo in Phase 3 Study Subgroups
Nov 13, 2020 09:15AM NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study S
Nov 13, 2020 09:14AM NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study S
Nov 6, 2020 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 6, 2020 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2020 04:01PM ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
Nov 2, 2020 04:01PM ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
Oct 27, 2020 08:00AM Esperion to Participate in Three Upcoming Virtual Investor Conferences
View More Recent Stories View Older Stories